Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide

• Status: Recruiting
• Trial end date: 2022-06-30
• Target enrollment: 0
• Participant gender: Male

Summary

To compare the effects of 40 mg once-daily Torsemide ER to 40 mg twice daily Furosemide on 24-hour sodium excretion.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sarfez Pharmaceuticals, Inc.
• Treatments: Furosemide; Torsemide

Criteria

Inclusion Criteria:

• Patients of either gender over 18 years of age with clinical diagnosis of CHF and on a stable dose of 40 mg Furosemide.

Exclusion Criteria:

• Requirement for any other diuretic, history of cardiac dysrhythmia, other concurrent cardiovascular illness.